secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2023-07-07T23:59:59+00:00
Accession:  0001104659-23-079096
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax amends Canada vaccine agreement; receives $349.6M in cash for forfeited doses
--------------------------------------------------------------------------------

- Canada pays $349.6M in two equal installments in 2023 for forfeited doses; first due upon execution.
- Remaining vaccine doses reduced and delivery schedule revised; BMC to be used for bulk antigen production in 2024-2025.
- Customer may terminate if Novavax fails to obtain regulatory approval for BMC by Dec 31, 2024.
- Total contract value unchanged; parties to explore expanded in-country commitment via Invest Canada MOU with $20M escrow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465923079096/0001104659-23-079096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465923079096/tm2320801d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-079096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer